18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study... by Bingbing Wen, Yuming Zhang, Haiqing Lin, Jin Lou, Chuangqing Tu, Yirong Jiang, Xiaolian Liu, Yan Chen, Huiqing He, Zelin Liu, Xiaoling Xie, Wangxiang Huang, Liping Pang, Xin Du

Get full text